

Figure 1




Figure 2




Figure 3

TITLE: TESTING ENDOSYMBIONT
CELLULAR ORGANELLES AND
COMPOUNDS IDENTIFIABLE THEREWITH

Inventor: van Gemen et al.

Serial No.: 10/006,009

Docket No.: 2183-5189US

3/22




Figure 4




Figure 5

10005009-03270
20/220" 60090001

4/22




Figure 6




Figure 7

TESTING ENDOSYMBIONT
CELLULAR ORGANELLES AND
COMPOUNDS IDENTIFIABLE THEREWITH

Inventor: van Gemen et al.

Serial No.: 10/006,009

Docket No.: 2183-5189US

5/22




Figure 8




Figure 9

TITLE: TESTING ENDOSYMBIONT
CELLULAR ORGANELLES AND
COMPOUNDS IDENTIFIABLE THEREWITH

Inventor: van Gemen et al.

Serial No.: 10/006,009

Docket No.: 2183-5189US

6/22




Figure 10

20/220" 60090001




Figure 11.

TITLE: TESTING ENDOSYMBIONT
CELLULAR ORGANELLES AND
COMPOUNDS IDENTIFIABLE THEREWITH


Inventor: van Gemen et al.

Serial No.: 10/006,009

Docket No.: 2183-5189US

8/22

Fig. 12



TITLE: TESTING ENDOSYMBIONT
CELLULAR ORGANELLES AND
COMPOUNDS IDENTIFIABLE THEREWITH


Inventor: van Gemen et al.

Serial No.: 10/006,009

Docket No.: 2183-5189US

9/22

Fig.13



1006009-032700

TITLE: TESTING ENDOSYMBIONT
CELLULAR ORGANELLES AND
COMPOUNDS IDENTIFIABLE THEREWITH


Inventor: van Gemen et al.

Serial No.: 10/006,009

Docket No.: 2183-5189US

10/22

Fig. 14



10006009.032702

202250 6009000T

Lactate acidose patient (H0224)

M10620 (H 0224)




Fig. 15A

FILE: TESTING ENDOSYMBIONT
CELLULAR ORGANELLES AND
COMPOUNDS IDENTIFIABLE THEREWITH

Inventor: van Gemen et al.

Serial No.: 10/006,009

Docket No.: 2183-5189US

11/22

Lactate acidose patient (H0224)





Fig. 15B

TITLE: TESTING ENDOSYMBIONT
CELLULAR ORGANELLES AND
COMPOUNDS IDENTIFIABLE THEREWITH



Inventor: van Gemen et al.

Serial No.: 10/006,009

Docket No.: 2183-5189US

13/22

Fig. 16



14/22




Fig. 17




Fig. 18

15/22




Fig. 19

204220" 6009000T

16/22

Significant decrease of mtDNA in PBMC





Fig. 20

17/22

Fig. 21

Copies mtDNA/cell for three individual patients












Fig. 22

19/22

20/230 6090001

Cultured fibroblasts with ddC



mtRNA -- nDNA duplex

Continued culture after ddC removal









Fig. 23

20/22 60090007

Adverse effects of antiretroviral therapy

Percentage of patients changing ART because of adverse effects
(results from the ATHENA-study in the Netherlands)




Fig. 24

DNA-NASBA amplification




Fig. 25

Mitochondria

location of primers for NASBA




Fig. 26